AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02811887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS-messages
Description: Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.~The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care).
Study NCT04921267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: training with filtered speech
Study NCT01537432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: secukinumab
Study NCT01967667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal glutathione
Description: Escalating dose steps
Study NCT01967667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: escalating dose steps
Study NCT01689207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avibactam (AVI)
Description: PART A: AVI IV infusion
Study NCT01689207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam (ATM)
Description: PART A: ATM IV infusion
Study NCT01689207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of Aztreonam - Avibactam (ATM-AVI)
Description: PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
Study NCT01689207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PART A, PART B, PART C: matching placebo IV infusions
Study NCT04423926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
Study NCT01537432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study NCT03412955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: 1.4mg/m2/dose on days 1 and 8 of a 21-day treatment cycle.
Study NCT01765387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spa session
Study NCT02921867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Description: The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
Study NCT00938626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
Description: After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
Study NCT00938626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
Study NCT04423926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 d1
Study NCT04423926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m2 d1
Study NCT04423926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4mg/m2 (maximum 2mg) d1
Study NCT04423926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 60mg/m2 d1-5
Study NCT00938626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
Study NCT00245479 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Primary nocturnal enuresis
Description: Desmopressin
Study NCT04480866 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Colli-Pee® (FV5000 and Small Volumes)
Description: Colli-Pee® device (Novosanis, Belgium) attached to collector tubes prefilled with a non-toxic nucleic acid preservative (including an internal process control). The collector tubes differ in size to collect a total sample volume of 4, 10, and 20 mL.~Each participant will collect three urine samples using the Colli-Pee Small Volumes 4 and 10 mL, and the Colli-Pee FV5000 (20 mL) device, in a random order.
Study NCT00057148 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: massage treatment
Study NCT02168556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Subject listens to music that is 60bpm while undergoing urodynamic testing.
Study NCT02168556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Subject watches an informational video prior to undergoing urodynamic testing.
Study NCT02168556 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT04418245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging by thoracic scanner
Description: Low-dose computed tomography
Study NCT01537328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total knee replacement rehabilitation
Description: After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
Study NCT01537328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement rehabilitation
Description: After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
Study NCT02902614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vegetal Pole blastomer embryo
Description: for day 3 embryo biopsy / cleavage stage
Study NCT02902614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Animal Pole blastomer embryo
Description: for day 3 embryo biopsy / cleavage stage
Study NCT03224884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Ultrasound guided brachial plexus block injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in the interscalene groove, under the prevertebral fascia.
Study NCT03224884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular block
Description: Ultrasound guided brachial plexus injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL (3 mL in the corner pocket followed by 17 mL posterolateral to the brachial plexus).
Study NCT03341936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
Study NCT03341936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
Study NCT00296712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram + bupropion
Description: same dosing as for monotherapy arms
Study NCT01146002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Guanfacine (sustained release)
Description: Treated with study drug once screening and initial testing is completed (see protocol above)
Study NCT04843592 — intervention group
Intervention type: DEVICE
Intervention: SOKARY Mobile
Description: Effectiveness of using SOKARY Mobile Application on compliance of patient with Type II diabetes
Study NCT02538796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEA + Grober Test + Task 1 + Grober Test
Description: The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words.
Study NCT02538796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEA + Grober Test + Task 1 + Grober Test
Description: The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words.
Study NCT02221700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Undergo massage therapy
Study NCT02221700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02538796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEA + Grober Test + Task 2 + Grober Test
Description: The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words.
Study NCT02538796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEA + Grober Test + Task 2 + Grober Test
Description: The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words.
Study NCT02538796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEA + Grober Test + Implicit Task 3 + Grober Test
Description: The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer).
Study NCT02538796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEA + Grober Test + Implicit Task 3 + Grober Test
Description: The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer).
Study NCT02538796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEA + Grober Test + Explicit Task 3 + Grober Test
Description: The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer).
Study NCT02538796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEA + Grober Test + Explicit Task 3 + Grober Test
Description: The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer).
Study NCT04118101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESPB block
Description: A total of 25 ml bupivacaine 0.5% will be injected into the ESP.
Study NCT04118101 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no ESPB will be given.
Study NCT02171728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study NCT00480532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lybrel
Description: All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
Study NCT00480532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lybrel
Description: All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
Study NCT00480532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
Study NCT00480532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oracea
Description: 40-mg tablet daily for 84 days
Study NCT00480532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
Study NCT00480532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100bid x5 days at the time of bleeding
Description: Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
Study NCT00480532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subantimicrobial doxycycline daily
Description: Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
Study NCT00480532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo daily
Description: Placebo daily for the first 84 days of the study
Study NCT01285102 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: irinotecan-eluting beads
Description: Patients will be treated with drug-eluting irinotecan beads per protocol at up to 100 mg per dose every 3 weeks. Patients will receive chemoembolization using LC Bead, loaded with irinotecan. The beads size range used in the study will be 100-300µm (nominal) with a dose of up to 100mg irinotecan per treatment. The beads will be mixed with a non-ionic contrast media in the vial immediately prior to use according to the instructions for use. Irinotecan will be loaded onto the beads not more than 2 hours prior to the procedure. The study goal will be to deliver the full dose of 100mg of irinotecan per treatment
Study NCT01285102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery embolization
Description: Using a unilateral femoral approach, selective catheterization of the hepatic artery will be performed. Vascular access is obtained via the common femoral artery and a guide-wire advanced under fluoroscopic guidance. A microcatheter is then inserted over the guide-wire. The superior mesenteric artery is selected and an angiogram performed to identify any aberrant arterial anatomy and verify antegrade portal vein flow. The celiac axis is then selected and an angiogram completed. The catheter and guide-wire are used to select the proper hepatic artery and a limited angiogram performed to identify the branches of the hepatic artery. The right or left hepatic artery is selected distal to the cystic artery (if visualized), depending on the location of the lesions to be treated. The LC Bead, loaded with irinotecan will be delivered into the artery.
Study NCT04131725 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Performance System (NSR)
Description: Device: Cardiac Performance System Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function. The device will be worn at the time when Pulmonary Artery Catheter procedures are conducted.
Study NCT01713608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: OZ439 x mg once daily for 3 days with milk
Study NCT01268020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FMH3
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of \[18F\]-FMH3, whichever is greatest.
Study NCT01987635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEMO 3D ring
Description: The experimental MEMO 3D ring is placed.
Study NCT01987635 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard use of rigid ring.
Description: The rigid ring is placed, which is standard procedure.
Study NCT01987635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Echocardiography
Study NCT01987635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D Echocardiography
Study NCT00513656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Study NCT00513656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone
Study NCT01254331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra]
Description: tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
Study NCT03488355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified laboratory report
Description: Report from microbiology laboratory: This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results.
Study NCT00516074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day
Study NCT04382092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FilmArray Pneumonia
Description: Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
Study NCT00329420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
Study NCT00329420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
Study NCT00329420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
Study NCT00756340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * Bevacizumab IV every 2 weeks~* Dose Level 0- 8 mg/kg~* Dose Level 1 (starting dose)- 10 mg/kg~* Dose Level 2- 10 mg/kg
Study NCT00756340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: * Everolimus~* Dose Level 0- 4 mg/m2~* Dose level 1 (starting dose)- 4 mg/m2~* Dose Level 2- 5 mg/m2
Study NCT00516074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, volume equivalent to active, twice a day
Study NCT00098956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00098956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV